SecBot SecBot
8-K ·Filed Jun 26, 2026

VXRT

Vaxart, Inc.
MIXED
Impact 5/10
Horizonweeks Processed4mo ago SEC0001437749-26-021833
8-K material event: Items 1.01
Actionable Insight ◆ Mixed

Monitor upcoming 12-month sentinel cohort data readout, which will be the first efficacy/safety signals from this large BARDA-funded Phase 2b trial. A positive result could drive significant upside given the stock's small clinical-stage biotech profile, but the funding cut by BARDA signals reduced government enthusiasm for the program.

DirectionMixed
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.5700
T+0 close · Jun 26, 2026 · via day close
Latest settled
−14.04%
T+60 · $0.4900
Vs SPY
−17.08%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $0.5700entry
  2. T+1 · 5mo ago +5.26%α +4.48% · $0.6000
  3. T+5 · 4mo ago +10.44%α +9.05% · $0.6295
  4. T+20 · 4mo ago −21.04%α −20.78% · $0.4501
  5. T+60 · 8w ago −14.04%α −17.08% · $0.4900

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vaxart entered Modification No. 7 to its BARDA Project Agreement, reducing total available funding by ~$116M to ~$345M following a ~50% participant reduction ordered by BARDA in August 2025. The modification releases ~$29M for trial completion and exploratory analyses, enabling Vaxart to report 12-month sentinel cohort data in the coming weeks and main cohort data in first half of 2027. While the funding cut reflects reduced government scope, the trial remains active with over 5,000 participants and near-term data catalysts.

Key Facts

  • Total BARDA funding reduced by ~$116M to ~$345M under Modification No. 7
  • Approximately 50% participant reduction due to BARDA partial termination ordered on August 5, 2025
  • Modification releases ~$29M for trial completion and exploratory safety/efficacy analyses
  • Vaxart expects to report 12-month sentinel cohort (400 participants) data in coming weeks
  • Main cohort (5,085 participants) data expected in first half of 2027
  • Funding includes ~$68M in firm fixed price amounts and remainder for cost reimbursement

Financial Impact

Total available BARDA funding decreased by approximately $116 million to approximately $345 million; $29 million released for trial completion

available_fundingtrial_scopedata_timeline

Risk Factors

  • Reduced trial scope may limit statistical power and commercial potential even if positive
  • Future milestone payments depend on achieving predefined endpoints under the contract
  • No guarantee of positive data; negative or equivocal sentinel results could be severely bearish
  • VXRT is a clinical-stage company with no approved products and relies on external funding

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-021833
Exhibit: ex_981693.htm0001437749-26-021833
Document: 0001437749-26-021833-index-headers.html0001437749-26-021833
Document: 0001437749-26-021833-index.html0001437749-26-021833
Document: 0001437749-26-021833.txt0001437749-26-021833

Track record

23 reports on VXRT

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +37.66% at T+60 after the May 1, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.3700 Now $0.3600 +2.70% settles Feb 4
  2. Oct 19, 202628d ago 8-K Neutral 3/10 Entry $0.4900 Now $0.3600 −26.53% settles Jan 15
  3. Jul 28, 202615w ago 8-K Neutral 2/10 Entry $0.4800 to $0.4900 Now $0.3600 −25.00% ▲ +2.08% −2.53% vs SPY
  4. Jul 7, 202618w ago 8-K Neutral 4/10 Entry $0.5500 to $0.4500 Now $0.3600 −34.55% ▼ −18.18% −21.27% vs SPY
  5. Jul 6, 202619w ago DEFA14A Neutral 5/10 Entry $0.6200 to $0.4540 Now $0.3600 −41.94% ▼ −26.77% −28.93% vs SPY
  6. Jul 2, 202619w ago DEFA14A Bullish 5/10 Entry $0.6400 to $0.4500 Now $0.3600 −43.75% ▼ −29.69% −33.51% vs SPY
  7. Jul 2, 202619w ago 8-K Neutral 4/10 Entry $0.6400 to $0.4520 Now $0.3600 −43.75% ▼ −29.38% −32.80% vs SPY
  8. Jun 26, 202620w ago DEFA14A Neutral 4/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  9. Jun 26, 202620w ago DEFA14A Neutral 3/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  10. Jun 26, 202620w ago 8-K Mixed 5/10 Viewing Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 26, 2026